Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Feb;73(4):429–432. doi: 10.1038/bjc.1996.77

Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin 4 receptor (CD 124).

M F Tungekar 1, K C Gatter 1, M A Ritter 1
PMCID: PMC2074450  PMID: 8595155

Abstract

Monoclonal antibody MR6 detects gp200-MR6, a molecule functionally associated with the interleukin 4 (IL- 4) receptor. Positive immunolabeling with MAb MR6 was obtained in 28/28 transitional cell carcinomas of the bladder, representing a range of different grades and stages of disease, as well as in all control non-neoplastic urothelia. The expression of mutant p53 protein and epidermal growth factor receptor was detected in 14/28 and 20/28 cases respectively. Proliferation indices, determined by Ki67 labeling, ranged from 5% to 95% among these tumours. The universal expression of gp200-MR6 in neoplastic and non-neoplastic urothelium has important implications for the possible use of IL-4 in tumour therapy and suggests that IL- 4 may play a role in differentiation and homeostasis of urothelium and other mucosal epithelia.

Full text

PDF
432

Images in this article

430Figure 1
on p.430
430Figure 2
on p.430
430Figure 3
on p.430
431Figure 4
on p.431

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al Jabaari B., Ladyman H. M., Larché M., Sivolapenko G. B., Epenetos A. A., Ritter M. A. Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy? Br J Cancer. 1989 Jun;59(6):910–914. doi: 10.1038/bjc.1989.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bukowski R. M., McLain D., Olencki T., Budd G. T., Murthy S. A. Interleukin-2: use in solid tumors. Stem Cells. 1993 Jan;11(1):26–32. doi: 10.1002/stem.5530110106. [DOI] [PubMed] [Google Scholar]
  3. Colombo M. P., Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today. 1994 Feb;15(2):48–51. doi: 10.1016/0167-5699(94)90131-7. [DOI] [PubMed] [Google Scholar]
  4. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  5. Costello R., Lipcey C., Olive D. Rationale for the utilization of interleukin-4, an immune-recognition induced cytokine, in cancer immunotherapy. Eur J Med. 1993 Jan;2(1):54–57. [PubMed] [Google Scholar]
  6. Debinski W., Puri R. K., Kreitman R. J., Pastan I. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J Biol Chem. 1993 Jul 5;268(19):14065–14070. [PubMed] [Google Scholar]
  7. Hermann G. G., Geertsen P. F., von der Maase H., Steven K., Andersen C., Hald T., Zeuthen J. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res. 1992 Feb 1;52(3):726–733. [PubMed] [Google Scholar]
  8. Imami N., Larché M., Ritter M. A. Inhibition of alloreactivity by mAb MR6: differential effects on IL-2- and IL-4- producing human T cells. Int Immunol. 1994 Oct;6(10):1575–1584. doi: 10.1093/intimm/6.10.1575. [DOI] [PubMed] [Google Scholar]
  9. Jansen J. H., Fibbe W. E., Willemze R., Kluin-Nelemans J. C. Interleukin-4. A regulatory protein. Blut. 1990 May;60(5):269–274. doi: 10.1007/BF01736226. [DOI] [PubMed] [Google Scholar]
  10. Kaklamanis L., Gatter K. C., Mortensen N., Harris A. L. Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. Br J Cancer. 1992 Oct;66(4):712–716. doi: 10.1038/bjc.1992.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kawakami Y., Haas G. P., Lotze M. T. Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4. J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):336–347. doi: 10.1097/00002371-199311000-00014. [DOI] [PubMed] [Google Scholar]
  12. Keegan A. D., Pierce J. H. The interleukin-4 receptor: signal transduction by a hematopoietin receptor. J Leukoc Biol. 1994 Feb;55(2):272–279. doi: 10.1002/jlb.55.2.272. [DOI] [PubMed] [Google Scholar]
  13. Lakkis F., Steele A., Pacheco-Silva A., Rubin-Kelley V., Strom T. B., Murphy J. R. Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein. Eur J Immunol. 1991 Sep;21(9):2253–2258. doi: 10.1002/eji.1830210937. [DOI] [PubMed] [Google Scholar]
  14. Larche M., Lamb J. R., O'Hehir R. E., Imami-Shita N., Zanders E. D., Quint D. E., Moqbel R., Ritter M. A. Functional evidence for a monoclonal antibody that binds to the human IL-4 receptor. Immunology. 1988 Dec;65(4):617–622. [PMC free article] [PubMed] [Google Scholar]
  15. Lotze M. T., Custer M. C., Bolton E. S., Wiebke E. A., Kawakami Y., Rosenberg S. A. Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications. Hum Immunol. 1990 Jun;28(2):198–207. doi: 10.1016/0198-8859(90)90020-p. [DOI] [PubMed] [Google Scholar]
  16. Mat I., Larche M., Melcher D., Ritter M. A. Tumour-associated upregulation of the IL-4 receptor complex. Br J Cancer Suppl. 1990 Jul;10:96–98. [PMC free article] [PubMed] [Google Scholar]
  17. Morisaki T., Uchiyama A., Yuzuki D., Essner R., Morton D. L., Hoon D. S. Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells. Cancer Res. 1994 Feb 15;54(4):1113–1118. [PubMed] [Google Scholar]
  18. Morisaki T., Yuzuki D. H., Lin R. T., Foshag L. J., Morton D. L., Hoon D. S. Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4. Cancer Res. 1992 Nov 1;52(21):6059–6065. [PubMed] [Google Scholar]
  19. Noguchi M., Nakamura Y., Russell S. M., Ziegler S. F., Tsang M., Cao X., Leonard W. J. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. 1993 Dec 17;262(5141):1877–1880. doi: 10.1126/science.8266077. [DOI] [PubMed] [Google Scholar]
  20. Obiri N. I., Hillman G. G., Haas G. P., Sud S., Puri R. K. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest. 1993 Jan;91(1):88–93. doi: 10.1172/JCI116205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Obiri N. I., Siegel J. P., Varricchio F., Puri R. K. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol. 1994 Jan;95(1):148–155. doi: 10.1111/j.1365-2249.1994.tb06029.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ozen H. Advances in bladder cancer. Curr Opin Oncol. 1993 May;5(3):574–580. doi: 10.1097/00001622-199305000-00020. [DOI] [PubMed] [Google Scholar]
  23. Paul W. E. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 1991 May 1;77(9):1859–1870. [PubMed] [Google Scholar]
  24. Paul W. E., Seder R. A. Lymphocyte responses and cytokines. Cell. 1994 Jan 28;76(2):241–251. doi: 10.1016/0092-8674(94)90332-8. [DOI] [PubMed] [Google Scholar]
  25. Redmond H. P., Schuchter L., Bartlett D., Kelly C. J., Shou J., Leon P., Daly J. M. Anti-neoplastic effects of interleukin-4. J Surg Res. 1992 Apr;52(4):406–411. doi: 10.1016/0022-4804(92)90124-i. [DOI] [PubMed] [Google Scholar]
  26. Russell S. M., Keegan A. D., Harada N., Nakamura Y., Noguchi M., Leland P., Friedmann M. C., Miyajima A., Puri R. K., Paul W. E. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science. 1993 Dec 17;262(5141):1880–1883. doi: 10.1126/science.8266078. [DOI] [PubMed] [Google Scholar]
  27. Stewart T. H., Tsai S. C. The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer. Clin Exp Metastasis. 1993 Jul;11(4):295–305. doi: 10.1007/BF00058049. [DOI] [PubMed] [Google Scholar]
  28. Tepper R. I. The anti-tumour and proinflammatory actions of IL4. Res Immunol. 1993 Oct;144(8):633–637. doi: 10.1016/s0923-2494(05)80017-3. [DOI] [PubMed] [Google Scholar]
  29. Toi M., Bicknell R., Harris A. L. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 1992 Jan 15;52(2):275–279. [PubMed] [Google Scholar]
  30. Topp M. S., Koenigsmann M., Mire-Sluis A., Oberberg D., Eitelbach F., von Marschall Z., Notter M., Reufi B., Stein H., Thiel E. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood. 1993 Nov 1;82(9):2837–2844. [PubMed] [Google Scholar]
  31. Totpal K., Aggarwal B. B. Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines. Cancer Res. 1991 Aug 15;51(16):4266–4270. [PubMed] [Google Scholar]
  32. Tungekar M. F., Turley H., Dunnill M. S., Gatter K. C., Ritter M. A., Harris A. L. Interleukin 4 receptor expression on human lung tumors and normal lung. Cancer Res. 1991 Jan 1;51(1):261–264. [PubMed] [Google Scholar]
  33. de Maagd R. A., MacKenzie W. A., Schuurman H. J., Ritter M. A., Price K. M., Broekhuizen R., Kater L. The human thymus microenvironment: heterogeneity detected by monoclonal anti-epithelial cell antibodies. Immunology. 1985 Apr;54(4):745–754. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES